ClinicalTrials.gg
Not yet recruitingNCT06535490PrePaCystUpdated Aug 2, 2024

Antibiotic Prophylaxis for EUS-FNA of Pancreatic Cystic Lesions

An observational study in Pancreatic Cystic Lesion, sponsored by Société Française d'Endoscopie Digestive. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-02.

Sponsored by Société Française d'Endoscopie Digestive · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,702
Ages
18 Years and older
Sex
All
01

Study summary

Large prospective comparative observational study in numerous reference centers in France, comparing infectious complications in patients admitted for pancreatic cystic lesions (PCL) aspiration performed with or without antibiotic prophylaxis (ATBp) according to the usual practices.

This is a prospective, comparative, observational, multicenter study, with the primary objective of comparing the infection rates in pancreatic cystic lesions (PCL) aspirated under EUS, with and without the administration of ATBp.

A sample size of 1702 patients will be needed over a 3-year study period.

Read the detailed description

The complication rate after EUS fine needle aspiration (EUS-FNA) for pancreatic cystic lesions (PCL) is low, around 1-3% according to various series. However, it has long been recommended to perform this procedure under antibiotic prophylaxis (ATBp). Due to the risk of developing resistance to certain classes of antibiotics and the risk of complications, particularly allergic reactions, the role of ATBp in this indication needs to be reconsidered. The latest recommendations from European and French societies do not support the systematic formal indication of ATBp for aspiration under EUS. Because the literature on the subject is sparse and equivocal, practices remain varied (some performing PCL aspirations with and others without ATBp), and scientific societies do not provide a formal stance on the benefit of such ATBp. Therefore, we decided to conduct a very large prospective comparative observational study in numerous reference centers in France (centers of the Research and Action Group in Endoscopy - GRAPHE), comparing infectious complications in patients admitted for EUS-FNA for PCL performed with or without ATBp according to the usual practices .

This is a prospective, comparative, observational, multicenter study.

Primary objective:

Comparison of infection rates after EUS-FNA for pancreatic cystic lesions (PCL) , with and without the administration of ATBp.

Secondary objectives:

Rates of other infectious complications (pulmonary, urinary, etc.) Rates of post-ATBp complications, particularly allergic reactions Prolongation of scheduled hospitalization Evaluation of factors associated with post-EUS aspiration infection of PCL

After the endoscopic exploration, the patient will be monitored for the potential occurrence of complications related to EUS (perforation, hemorrhage, infection, allergy, etc.). Any adverse events will be recorded at 30 days post-procedure.

A sample size of 1702 patients will be needed over a 3-year study period.

02

Conditions studied

  • Pancreatic Cystic Lesion

Keywords

  • EUS-FNA
  • Pancreatic cystic lesion
  • Antibiotic prophylaxis
03

In context

Lead sponsor

Société Française d'Endoscopie Digestive is the lead sponsor of 25 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with pancreatic cystic lesions for whom an EUS-FNA is indicated

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient referred for diagnostic aspiration of a pancreatic cystic lesion
  • Patient aged 18 years or older
  • Patient with ASA 1, ASA 2, ASA 3 status
  • No participation in another concurrent clinical study

Exclusion criteria

Exclusion Criteria:

  • Patient under 18 years old
  • Patient with ASA 4 or ASA 5 status
  • Pregnant woman
  • Patient with coagulation disorders preventing the performance of an EUS-FNA: PT \< 50%, \< 50,000/mm³, current effective anticoagulation, ongoing clopidogrel, prasugrel, or ticagrelor treatment
  • Patient unable to personally express non-opposition or legally protected adult
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,702 participants (estimated)
Patient registry
No

Groups and cohorts

  • EUS-FNA for PCL with ATBp

    Patients undergoing EUS-FNA for pancreatic cystic lesions WITH ATBp

    Procedure: EUS-FNA · Drug: ATBp

  • EUS-FNA for PCL without ATBp

    Patients undergoing EUS-FNA for pancreatic cystic lesions without ATBp

    Procedure: EUS-FNA

Interventions

  • ProcedureEUS-FNA

    Puncture of pancreatic cystic lesion with a fine needle under EUS guidance

    Also known as: EUS fine needle aspiration

  • DrugATBp

    Antibiotic prophylaxis consists of a single intravenous administration before or at the beginning of the procedure according to the common practices of each practitioner or unit

    Also known as: Antibiotic prophylaxis

06

What researchers measure

Primary outcomes

  1. Post EUS-FNA PCL infection rate

    Post-EUS-FNA infection rate of PCL (patients exhibiting clinical and biological signs - fever \>38.5°C, neutrophilic leukocytosis, elevated CRP, pathogen identification in blood cultures - indicative of sepsis requiring prolonged antibiotic therapy). The occurrence of the aforementioned clinical and biological signs, along with imaging evidence (such as cyst wall thickening or presence of intracystic air images) and the absence of another infection source (urinary, pulmonary, venous, etc.) will lead to the diagnosis of post-FNA infection. Centralized validation of infection cases will be conducted by an expert panel based on clinical, biological, and imaging findings.

    Time frame: 30 days

Secondary outcomes

  1. Rate of urinary infectious complications

    Number of patients with at least one urinary infection within 21-30 days after EUS-FNA

    Time frame: 30 days

  2. Rate of post-ATBp allergic reactions

    Number of patients with at least one allergic reaction within 21-30 days after EUS-FNA

    Time frame: 30 days

  3. Duration and extension of hospitalization

    Number of hospitalization days per stay within 30 days following EUS-FNA

    Time frame: 30 days

  4. Diameter of the needle used for EUS-FNA

    25G, 22G, 20G, or 19G

    Time frame: 1 days

  5. Associated procedures (confocal endomicroscopy or intracystic biopsy)

    Yes or No

    Time frame: 1 days

  6. Appearance of the fluid

    Thin, thick, hemorrhagic

    Time frame: 1 day

  7. Complete aspiration of the cyst fluid

    Yes or No

    Time frame: 1 day

  8. Nature of the PCL

    mucinous vs. non-mucinous

    Time frame: 30 days

  9. Age

    Years

    Time frame: 1 day

  10. Gender

    Male or female

    Time frame: 1 day

  11. Diabetes

    Yes or No

    Time frame: 1 day

  12. Immunosuppression

    Yes or No

    Time frame: 1 day

  13. BMI

    Weight/(size)2 expressed in in kg/m\^2

    Time frame: 1 day

  14. history of aspiration of the same lesion

    Yes or No

    Time frame: 1 day

  15. Rate of pulmonary infectious complications

    Number of patients with at least one pulmonary infection within 21-30 days after EUS-FNA

    Time frame: 30 days

07

Study locations

1 site
08

References and documents

Publications

  • Polkowski M, Jenssen C, Kaye P, Carrara S, Deprez P, Gines A, Fernandez-Esparrach G, Eisendrath P, Aithal GP, Arcidiacono P, Barthet M, Bastos P, Fornelli A, Napoleon B, Iglesias-Garcia J, Seicean A, Larghi A, Hassan C, van Hooft JE, Dumonceau JM. Technical aspects of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Technical Guideline - March 2017. Endoscopy. 2017 Oct;49(10):989-1006. doi: 10.1055/s-0043-119219. Epub 2017 Sep 12. PubMed 28898917 ↗
  • Facciorusso A, Mohan BP, Tacelli M, Crino SF, Antonini F, Fantin A, Barresi L. Use of antibiotic prophylaxis is not needed for endoscopic ultrasound-guided fine-needle aspiration of pancreatic cysts: a meta-analysis. Expert Rev Gastroenterol Hepatol. 2020 Oct;14(10):999-1005. doi: 10.1080/17474124.2020.1797486. Epub 2020 Jul 25. PubMed 32674699 ↗
  • Facciorusso A, Arevalo-Mora M, Conti Bellocchi MC, Bernardoni L, Ramai D, Gkolfakis P, Loizzi D, Muscatiello N, Ambrosi A, Tartaglia N, Robles-Medranda C, Stasi E, Ofosu A, Crino SF. Impact of Antibiotic Prophylaxis on Infection Rate after Endoscopic Ultrasound Through-the-Needle Biopsy of Pancreatic Cysts: A Propensity Score-Matched Study. Diagnostics (Basel). 2022 Jan 16;12(1):211. doi: 10.3390/diagnostics12010211. PubMed 35054378 ↗
  • Facciorusso A, Buccino VR, Turco A, Antonino M, Muscatiello N. Antibiotics Do Not Decrease the Rate of Infection After Endoscopic Ultrasound Fine-Needle Aspiration of Pancreatic Cysts. Dig Dis Sci. 2019 Aug;64(8):2308-2315. doi: 10.1007/s10620-019-05655-x. Epub 2019 May 7. PubMed 31065897 ↗
  • Klein A, Qi R, Nagubandi S, Lee E, Kwan V. Single-dose intra-procedural ceftriaxone during endoscopic ultrasound fine-needle aspiration of pancreatic cysts is safe and effective: results from a single tertiary center. Ann Gastroenterol. 2017;30(2):237-241. doi: 10.20524/aog.2016.0118. Epub 2016 Dec 22. PubMed 28243046 ↗
  • Guarner-Argente C, Shah P, Buchner A, Ahmad NA, Kochman ML, Ginsberg GG. Use of antimicrobials for EUS-guided FNA of pancreatic cysts: a retrospective, comparative analysis. Gastrointest Endosc. 2011 Jul;74(1):81-6. doi: 10.1016/j.gie.2011.03.1244. PubMed 21704808 ↗
  • Lee LS, Saltzman JR, Bounds BC, Poneros JM, Brugge WR, Thompson CC. EUS-guided fine needle aspiration of pancreatic cysts: a retrospective analysis of complications and their predictors. Clin Gastroenterol Hepatol. 2005 Mar;3(3):231-6. doi: 10.1016/s1542-3565(04)00618-4. PubMed 15765442 ↗
  • Colan-Hernandez J, Sendino O, Loras C, Pardo A, Gornals JB, Concepcion M, Sanchez-Montes C, Murzi M, Andujar X, Velasquez-Rodriguez J, Rodriguez de Miguel C, Fernandez-Esparrach G, Gines A, Guarner-Argente C. Antibiotic Prophylaxis Is Not Required for Endoscopic Ultrasonography-Guided Fine-Needle Aspiration of Pancreatic Cystic Lesions, Based on a Randomized Trial. Gastroenterology. 2020 May;158(6):1642-1649.e1. doi: 10.1053/j.gastro.2020.01.025. Epub 2020 Jan 20. PubMed 31972236 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2024; primary completion for Sep 2027, 36 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2024
First posted
Aug 2, 2024
StartEst.
Sep 15, 2024
Primary completionEst.
Sep 15, 2027
CompletionEst.
Oct 15, 2027
Last update
Aug 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06535490
Lead sponsor
Société Française d'Endoscopie Digestive
Responsible party
David KARSENTI (Medical doctor, Principal Investigator, Société Française d'Endoscopie Digestive) — Principal investigator
First posted
Aug 2, 2024
Start date
Sep 15, 2024 (estimated)
Primary completion
Sep 15, 2027 (estimated)
Completion
Oct 15, 2027 (estimated)
Last update
Aug 2, 2024

Study contacts

David KARSENTI, MD
Contact
karsenti.paris@gmail.com
+33 1 43 96 78 50
David KARSENTI
study chair · Societe Française d'Endoscopie Digestive

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion